Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Non Operating Investment Income: 2019-2024

Historic Non Operating Investment Income for ImmunityBio (IBRX) over the last 6 years, with Dec 2024 value amounting to $8.0 million.

  • ImmunityBio's Non Operating Investment Income rose 14.96% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 27.20%. This contributed to the annual value of $8.0 million for FY2024, which is 605.13% up from last year.
  • According to the latest figures from FY2024, ImmunityBio's Non Operating Investment Income is $8.0 million, which was up 605.13% from $1.1 million recorded in FY2023.
  • ImmunityBio's Non Operating Investment Income's 5-year high stood at $8.0 million during FY2024, with a 5-year trough of -$4.1 million in FY2021.
  • Over the past 3 years, ImmunityBio's median Non Operating Investment Income value was $1.1 million (recorded in 2023), while the average stood at $2.0 million.
  • As far as peak fluctuations go, ImmunityBio's Non Operating Investment Income crashed by 268.38% in 2021, and later spiked by 605.13% in 2024.
  • Yearly analysis of 5 years shows ImmunityBio's Non Operating Investment Income stood at $2.4 million in 2020, then slumped by 268.38% to -$4.1 million in 2021, then increased by 24.63% to -$3.1 million in 2022, then skyrocketed by 136.60% to $1.1 million in 2023, then soared by 605.13% to $8.0 million in 2024.